Payment overview · 2025
General Payments
$952.97
49 reported records · 18 companies
Healthcare provider profile · identity verified
Amanda A Dove, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROGERSVILLE, TN · NPI 1093978330
Verified facts
What the public records show
CMS Open Payments records show Amanda A Dove, MD received $952.97 in general payments during 2025 across 49 reported records.
Novo Nordisk Inc accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $204.67 | 21.5% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.76 | 15.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $127.18 | 13.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.99 | 6.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.48 | 6.5% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $52.98 | 5.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.86 | 4.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.90 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.92 | 3.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.28 | 2.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.60 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.38 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.90 | 2.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.60 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.51 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.76 | 1.8% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $16.74 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.46 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $952.97 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $184.87 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $137.78 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $130.90 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $127.18 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $122.47 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $108.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.99 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.48 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $61.48 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $42.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 256 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
96 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
256 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
256 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 797 | 210 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 700 | 110 |
| Omeprazole | Omeprazole | 626 | 162 |
| Lisinopril | Lisinopril | 605 | 157 |
| Gabapentin | Gabapentin | 595 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 494 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 430 | 114 |
| Hydrochlorothiazide | Hydrochlorothiazide | 423 | 111 |
| Metformin Hcl | Metformin Hcl | 411 | 104 |
| Trazodone Hcl | Trazodone Hcl | 393 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 392 | 106 |
| Losartan Potassium | Losartan Potassium | 361 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 331 | 81 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 328 | 45 |
| Furosemide | Furosemide | 304 | 89 |
| Simvastatin | Simvastatin | 296 | 75 |
| Clonazepam | Clonazepam | 291 | 37 |
| Alprazolam | Alprazolam | 273 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 264 | 30 |
| Meloxicam | Meloxicam | 259 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 258 | 68 |
| Eliquis | Apixaban | 256 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 250 | 70 |
| Tramadol Hcl | Tramadol Hcl | 249 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 69 |
| Doxycycline Hyclate | Doxycycline Hyclate | 217 | 141 |
| Famotidine | Famotidine | 217 | 61 |
| Atenolol | Atenolol | 214 | 49 |
| Montelukast Sodium | Montelukast Sodium | 210 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 48 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 179 | 54 |
| Potassium Chloride | Potassium Chloride | 178 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 175 | 43 |
| Methylprednisolone | Methylprednisolone | 173 | 125 |
| Glimepiride | Glimepiride | 172 | 52 |
| Diazepam | Diazepam | 171 | 21 |
| Ozempic | Semaglutide | 166 | 38 |
| Allopurinol | Allopurinol | 152 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 147 | 27 |
| Carvedilol | Carvedilol | 141 | 36 |
| Lorazepam | Lorazepam | 134 | 23 |
| Sertraline Hcl | Sertraline Hcl | 132 | 33 |
| Spironolactone | Spironolactone | 129 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 36 |
| Bupropion Xl | Bupropion Hcl | 121 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 39 |
| Ondansetron Odt | Ondansetron | 106 | 39 |
| Bupropion Hcl Sr | Bupropion Hcl | 104 | 23 |
| Pregabalin | Pregabalin | 103 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 22 |
| Metformin Hcl Er | Metformin Hcl | 97 | 29 |
| Buspirone Hcl | Buspirone Hcl | 96 | 26 |
| Linzess | Linaclotide | 96 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 20 |
| Fluconazole | Fluconazole | 92 | 47 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 89 | 20 |
| Lovastatin | Lovastatin | 86 | 21 |
| Ibuprofen | Ibuprofen | 81 | 26 |
| Promethazine Hcl | Promethazine Hcl | 79 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 79 | 51 |
| Azithromycin | Azithromycin | 77 | 61 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 18 |
| Synthroid | Levothyroxine Sodium | 77 | 16 |
| Jardiance | Empagliflozin | 76 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 75 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 18 |
| Mirtazapine | Mirtazapine | 73 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 19 |
| Warfarin Sodium | Warfarin Sodium | 73 | 11 |
| Chlorthalidone | Chlorthalidone | 72 | 18 |
| Azelastine Hcl | Azelastine Hcl | 68 | 31 |
| Topiramate | Topiramate | 66 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 30 |
| Celecoxib | Celecoxib | 64 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 43 |
| Donepezil Hcl | Donepezil Hcl | 63 | 21 |
| Fenofibrate | Fenofibrate | 63 | 16 |
| Nystatin | Nystatin | 59 | 29 |
| Prednisone | Prednisone | 59 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 13 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 24 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 51 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 12 |
| Mounjaro | Tirzepatide | 50 | 11 |
| Baclofen | Baclofen | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Sucralfate | Sucralfate | 47 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | 13 |
| Amoxicillin | Amoxicillin | 45 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Glipizide | Glipizide | 44 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Irbesartan | Irbesartan | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Finasteride | Finasteride | 38 | 14 |
| Nabumetone | Nabumetone | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 14 |
| Valacyclovir | Valacyclovir Hcl | 34 | 13 |
| Valsartan | Valsartan | 34 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 31 | 25 |
| Nitroglycerin | Nitroglycerin | 31 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 11 |
| Cephalexin | Cephalexin | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Savella | Milnacipran Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $952.97 · 49 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Auvelity, BREZTRI, ELIQUIS, EVENITY, FARXIGA, GEMTESA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error